Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
10 2021
Historique:
pubmed: 26 5 2021
medline: 30 9 2021
entrez: 25 5 2021
Statut: ppublish

Résumé

Our primary objective is to detail the incidence, site, and timing of penile squamous cell carcinoma (pSCC) recurrence after inguinal lymph node dissection (ILND). We performed a retrospective analysis of 551 patients who underwent ILND for pSCC from 2000 to 2017. The primary outcome was pSCC recurrence after ILND. Recurrences were identified and stratified by site. Timing of recurrence was determined. Multivariable logistic regression analysis determined associations with recurrence. Multivariable Cox regression analysis determined associations with overall survival (OS). Sub-group analysis of the distant recurrences analyzed timing and OS by site of distant recurrence. After ILND pSCC recurred in 176 (31.9%) patients. Median time to recurrence was 10 months for distant recurrences, 12 for inguinal, 10.5 for pelvic, and 44.5 for local. Greater than 95% of distant, inguinal, and pelvic recurrences occurred within 48 months of ILND, versus 127 months for local recurrences. Post-ILND recurrence was associated with pN2 (OR 1.99, 95% CI 1.0-4.1), and pN3 (OR 7.2, 95% CI 4.0-13.7). Patients who had local recurrence had similar OS to those without (HR 1.5, 95% CI 0.6-3.8), and worse OS was identified in patients with inguinal (HR 4.5, 95% CI 2.8-7.1), pelvic (HR 2.6, 95% CI 1.5-4.5), or distant (HR 4.0, 95% CI 2.7-5.8) recurrences. Patients with lung recurrences had worse OS than other sites (HR 2.2, 95% CI 1.1-4.3). Of the patients 31.9% had post-ILND recurrence associated with high pN staging. Greater than 95% of distant, inguinal, and pelvic recurrences occurred within 48 months, suggesting surveillance beyond this is low yield. Local recurrences occurred over a longer timeline, emphasizing necessity of long-term surveillance of the primary site.

Identifiants

pubmed: 34032492
doi: 10.1097/JU.0000000000001790
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

960-969

Commentaires et corrections

Type : CommentIn

Auteurs

Nicholas H Chakiryan (NH)

H. Lee Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, Florida.

Aaron Dahmen (A)

University of South Florida, Department of Urology, Tampa, Florida.

Marco Bandini (M)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Filippo Pederzoli (F)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Laura Marandino (L)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Maarten Albersen (M)

University Hospitals Leuven, Leuven, Belgium.

Eduard Roussel (E)

University Hospitals Leuven, Leuven, Belgium.

Yao Zhu (Y)

Fudan University Shanghai Cancer Center, Shanghai, China.

Ding-Wei Ye (DW)

Fudan University Shanghai Cancer Center, Shanghai, China.

Antonio A Ornellas (AA)

Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil.

Mario Catanzaro (M)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Oliver W Hakenberg (OW)

University Hospital Rostock, Rostock, Germany.

Axel Heidenreich (A)

Universitätsklinikum Köln, Köln, Germany.

Friederike Haidl (F)

Universitätsklinikum Köln, Köln, Germany.

Nick Watkin (N)

Universitätsklinikum Köln, Köln, Germany.

Michael Ager (M)

Universitätsklinikum Köln, Köln, Germany.

Jad Chahoud (J)

H. Lee Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, Florida.

Alberto Briganti (A)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Roberto Salvioni (R)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Francesco Montorsi (F)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Andrea Necchi (A)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Philippe E Spiess (PE)

H. Lee Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, Florida.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH